Assertio Holdings Inc traded at $19.39 this Friday March 27th, decreasing $0.14 or 0.72 percent since the previous trading session. Looking back, over the last four weeks, Assertio Holdings lost 64.74 percent. Over the last 12 months, its price rose by 86.88 percent. Looking ahead, we forecast Assertio Holdings Inc to be priced at 18.01 by the end of this quarter and at 16.44 in one year, according to Trading Economics global macro models projections and analysts expectations.
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company's commercial portfolio of branded products focuses on three areas: neurology, hospital, and pain and inflammation. Its marketed products include Cambia (diclofenac potassium) for Oral solution, INDOCIN Oral Suspension, INDOCIN (indomethacin) Suppositories, OXAYDO (oxycodone HCI, USP) tablets, SPRIX (ketorolac tromethamine) Nasal Spray, and ZIPSOR (diclofenac potassium) Liquid filled capsules. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis. CAMBIA (diclofenac potassium) is used for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older.